Akari Therapeutics (NASDAQ:AKTX) reported positive results from the first three bullous pemphigoid (BP) patients in an ongoing Phase 2 clinical trial. BP is a severe orphan inflammatory skin disease characterized by...
Researchers at the University of Southern California’s (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T treatment that reduces the risk of cytokine release syndrome (CRS), a dangerous immune...
Alder BioPharma (NASDAQ:ALDR) BLA application for eptinezumab, a monoclonal antibody for the prevention of migraines, has been accepted by the FDA. Administered intravenously, eptinezumab targets and suppresses...
Autolus Therapeutics’ (NASDAQ:AUTL) AUTO3 has received FDA orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL). AUTO3 is a T-cell therapy produced by genetically modifying a patient’s own T...
Sensus Healthcare’s (NASDAQ:SRTS) superficial radiation therapy (SRT) demonstrated a 98.9% skin cancer cure in a five-year retrospective study. Sensus’ SRT is a low-energy X-ray technology used to treat non-melanoma...
Catasys (NASDAQ:CATS) entered into an agreement with Optima Health to provide its OnTrak solution to eligible commercial members in Virginia, with a launch expected in the second quarter of 2019. Catasys applies...
IntelGenx (TSXV:IGX; OTCQX:IGXT) plans to demonstrate the capabilities of its contract development and manufacturing organization (CDMO) services and its VersaFilm and VetaFilm oral film technologies, at CPhI North...
BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...
Privately-held NeuroSigma has received FDA approval to market its Monarch external Trigeminal Nerve Stimulation (eTNS) System to attention deficit hyperactivity disorder (ADHD) patients. Indicated in patients from...
Molecular Templates (NASDAQ:MTEM) IND application for MT-5111, an engineered toxin body targeting HER2, has been accepted by the FDA. MT-5111’s single chain variable fragment and Shiga-like toxin-A subunit respectively...